Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5290687 | 1.00 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GRM1 | |
| SCHEMBL4437211 | 0.79 | GRIA1 (0.36) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL13319959 | 0.77 | BLM (0.39) | GRIA1GRIA3GRIA4MEN1KMT2A | |
| SCHEMBL5062987 | 0.77 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL22407293 | 0.77 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4GAA | |
| Aspartic Acid SCHEMBL5964784 | 0.74 | GRIA1 (0.43) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL10006896 | 0.71 | GRIA1 (0.46) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL16415150 | 0.71 | GRIA1 (0.32) | GRIA1GRIA3 | |
| SCHEMBL1340851 | 0.71 | GRIA1 (0.32) | GRIA1GRIA3 | |
| (R,S)-Ampa SCHEMBL2458874 | 0.70 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRIA1 22/4885GRIA3 18/4885GRIA2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.